Loading...
Market
What will be the effectiveness of the updated mRNA COVID-19 vaccine against the JN.1 strain by June 30, 2025?
2
Resolution / Starting Odds
Less than 50% • 25%
50-70% • 25%
71-90% • 25%
More than 90% • 25%
Peer-reviewed medical journals and official health reports
Story
Japan Approves CSL and Arcturus Therapeutics' Updated mRNA COVID-19 Vaccine for JN.1 Strain, Distributed by Meiji Seika Pharma
Sep 13, 2024, 12:04 PM
Japan's Ministry of Health, Labor and Welfare has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA COVID-19 vaccine for protection against the JN.1 strain. The vaccine will be distributed in Japan by Meiji Seika Pharma. This approval marks a significant step in Japan's efforts to combat the ongoing pandemic, leveraging advanced mRNA technology to enhance immunity against emerging strains. CSL and Meiji Seika Pharma are key players in this initiative.
View original story
Similar markets
Pfizer (KP.2) • 25%
Moderna (KP.2) • 25%
Novavax (JN.1) • 25%
All equally effective • 25%
Yes • 50%
No • 50%
Very Positive • 25%
Somewhat Positive • 25%
Neutral • 25%
Negative • 25%
Very Effective (>90%) • 25%
Effective (70-90%) • 25%
Moderately Effective (50-70%) • 25%
Ineffective (<50%) • 25%
Yes • 50%
No • 50%
Highly effective • 25%
Moderately effective • 25%
Slightly effective • 25%
Not effective • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%